Talecris Biotherapeutics study shows that Prolastin-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as Prolastin (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PROLASTIN was launched in the U.S. in February 1988 as the first and only FDA-approved therapy for the treatment of alpha1 by augmenting patients' levels of the alpha1-antitrypsin protein. Twenty-five ...

"For nearly 17 years, PROLASTIN was the only product available to patients with Alpha-1," said Dr. Sandy Sandhaus, Professor of Medicine and Director, Alpha 1-Antitrypsin Deficiency Program at ...

RESEARCH TRIANGLE PARK, N.C., Oct. 19 Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), ...

The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) ...

BARCELONA, Spain, July 13, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced it has met its ...

PROLASTIN - C and PROLASTIN are indicated for the treatment of alpha 1 -antitrypsin (AAT) deficiency in patients with panacinar emphysema. AAT deficiency is a genetic condition in which low levels of ...

PROLASTIN was launched in the U.S. in February 1988 as the first and only FDA-approved therapy for the treatment of alpha1 by augmenting patients' levels of the alpha 1 -antitrypsin protein.

Alpha1-proteinase inhibitor (human) 1000mg/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.